Patrick Lefèbvre

10.5k total citations · 2 hit papers
469 papers, 7.3k citations indexed

About

Patrick Lefèbvre is a scholar working on Cardiology and Cardiovascular Medicine, Pulmonary and Respiratory Medicine and Psychiatry and Mental health. According to data from OpenAlex, Patrick Lefèbvre has authored 469 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 89 papers in Cardiology and Cardiovascular Medicine, 88 papers in Pulmonary and Respiratory Medicine and 73 papers in Psychiatry and Mental health. Recurrent topics in Patrick Lefèbvre's work include Atrial Fibrillation Management and Outcomes (63 papers), Venous Thromboembolism Diagnosis and Management (51 papers) and Health Systems, Economic Evaluations, Quality of Life (50 papers). Patrick Lefèbvre is often cited by papers focused on Atrial Fibrillation Management and Outcomes (63 papers), Venous Thromboembolism Diagnosis and Management (51 papers) and Health Systems, Economic Evaluations, Quality of Life (50 papers). Patrick Lefèbvre collaborates with scholars based in United States, Canada and France. Patrick Lefèbvre's co-authors include Mei Sheng Duh, Dominic Pilon, Marie‐Hélène Lafeuille, François Laliberté, Kruti Joshi, Jeff Schein, Bruno Émond, Winnie W. Nelson, Brahim Bookhart and Maryia Zhdanava and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Patrick Lefèbvre

447 papers receiving 7.1k citations

Hit Papers

The Prevalence and Nation... 2021 2026 2022 2024 2021 2022 50 100 150 200 250
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Prevalence and National Burden of Treatment-Resistant Depression and Major Depressive Disorder in the United States
    2021 296 citations Maryia Zhdanava, Dominic Pilon et al. profile →
  2. The Economic Burden of Posttraumatic Stress Disorder in the United States From a Societal Perspective
    2022 108 citations Jeff Schein, Martin Cloutier et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Patrick Lefèbvre 1.5k 1.3k 880 862 717 469 7.3k
Erzsébet Horváth–Puhó 1.7k 1.1× 621 0.5× 706 0.8× 1.8k 2.1× 419 0.6× 215 7.0k
Ad A. Kaptein 451 0.3× 896 0.7× 762 0.9× 426 0.5× 609 0.8× 156 5.5k
Michel Cucherat 1.9k 1.3× 1.2k 0.9× 570 0.6× 474 0.5× 275 0.4× 182 8.1k
Birgitta Stegmayr 2.2k 1.5× 619 0.5× 1.2k 1.3× 379 0.4× 924 1.3× 108 8.1k
Fabio Pellegrini 2.0k 1.3× 858 0.6× 511 0.6× 164 0.2× 767 1.1× 201 10.7k
Nicholas L. Smith 2.1k 1.4× 293 0.2× 498 0.6× 669 0.8× 513 0.7× 187 6.8k
Christian Mallen 420 0.3× 780 0.6× 879 1.0× 194 0.2× 479 0.7× 423 8.8k
Cheryl Bushnell 3.9k 2.6× 2.1k 1.6× 2.9k 3.2× 1.6k 1.9× 653 0.9× 186 14.2k
Cynthia L. Leibson 2.1k 1.4× 1.2k 0.9× 552 0.6× 337 0.4× 478 0.7× 91 9.3k
Petra Otterblad Olausson 1.2k 0.9× 832 0.6× 914 1.0× 143 0.2× 472 0.7× 64 8.5k

Countries citing papers authored by Patrick Lefèbvre

Since Specialization
Citations

This map shows the geographic impact of Patrick Lefèbvre's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Patrick Lefèbvre with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Patrick Lefèbvre more than expected).

Fields of papers citing papers by Patrick Lefèbvre

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Patrick Lefèbvre. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Patrick Lefèbvre. The network helps show where Patrick Lefèbvre may publish in the future.

Co-authorship network of co-authors of Patrick Lefèbvre

This figure shows the co-authorship network connecting the top 25 collaborators of Patrick Lefèbvre. A scholar is included among the top collaborators of Patrick Lefèbvre based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Patrick Lefèbvre. Patrick Lefèbvre is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Kaye, Deborah R., Erik Muser, Laura Morrison, et al.. (2024). Characterizing the real-world economic burden of metastatic castration-sensitive prostate cancer in the United States. Journal of Medical Economics. 27(1). 381–391. 2 indexed citations
2.
Fitzgerald, Timothy, Maryia Zhdanava, Dominic Pilon, et al.. (2023). Long-Term Psoriasis Control with Guselkumab, Adalimumab, Secukinumab, or Ixekizumab in the USA. Dermatology and Therapy. 13(4). 1053–1068. 13 indexed citations
3.
DeMartino, Jessica K., Marie‐Hélène Lafeuille, Bruno Émond, et al.. (2023). Respiratory Syncytial Virus–Related Complications and Healthcare Costs Among a Medicare-Insured Population in the United States. Open Forum Infectious Diseases. 10(5). ofad203–ofad203. 7 indexed citations
4.
Zhdanava, Maryia, Timothy Fitzgerald, Dominic Pilon, et al.. (2023). 43312 Long term psoriasis control with guselkumab versus secukinumab and ixekizumab among bio- experienced patients: analysis of drug persistence in large claims database. Journal of the American Academy of Dermatology. 89(3). AB188–AB188. 1 indexed citations
5.
Neul, Jeffrey L., et al.. (2023). Real-world clinical management of individuals with Rett syndrome: a physician survey. Journal of Medical Economics. 26(1). 1570–1580. 2 indexed citations
6.
Fitzgerald, Timothy, Maryia Zhdanava, Dominic Pilon, et al.. (2023). 43038 Long term psoriasis control with guselkumab versus secukinumab and ixekizumab among bio- naïve patients: analysis of drug persistence in large claims database. Journal of the American Academy of Dermatology. 89(3). AB188–AB188. 1 indexed citations
7.
DuBrock, Hilary M., Hayley D. Germack, Marjolaine Gauthier‐Loiselle, et al.. (2023). Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH). PharmacoEconomics - Open. 8(1). 133–146. 3 indexed citations
8.
Lu, Xiaoxiao, Bruno Émond, Zaina P. Qureshi, et al.. (2023). Real-world time to discontinuation of first-line venetoclax + obinutuzumab in chronic lymphocytic leukemia/small lymphocytic lymphoma. Current Medical Research and Opinion. 39(9). 1227–1235. 1 indexed citations
9.
Lu, Xiaoxiao, Bruno Émond, Laura Morrison, et al.. (2023). Real-World Comparison of First-Line Treatment Adherence Between Single-Agent Ibrutinib and Acalabrutinib in Patients with Chronic Lymphocytic Leukemia. Patient Preference and Adherence. Volume 17. 2073–2084. 3 indexed citations
10.
Berger, Jeffrey S., François Laliberté, Dominique Lejeune, et al.. (2022). Effectiveness, safety, and healthcare costs associated with rivaroxaban versus warfarin among venous thromboembolism patients with obesity: a real-world study in the United States. Journal of Thrombosis and Thrombolysis. 54(3). 438–448. 6 indexed citations
11.
Melsheimer, Richard, Rachel H. Bhak, Patrick Lefèbvre, et al.. (2022). Impact of switching to infliximab biosimilars on treatment patterns among US veterans receiving innovator infliximab. Current Medical Research and Opinion. 38(4). 613–627. 5 indexed citations
12.
Berger, Jeffrey S., François Laliberté, Dominique Lejeune, et al.. (2021). Real-world effectiveness and safety of rivaroxaban versus warfarin among non-valvular atrial fibrillation patients with obesity in a US population. Current Medical Research and Opinion. 37(6). 881–890. 16 indexed citations
13.
Young, James B., Marjolaine Gauthier‐Loiselle, Robert A. Bailey, et al.. (2018). Development of predictive risk models for major adverse cardiovascular events among patients with type 2 diabetes mellitus using health insurance claims data. Cardiovascular Diabetology. 17(1). 118–118. 31 indexed citations
14.
Kageleiry, Andrew, et al.. (2016). Out‐of‐pocket medical costs and third‐party healthcare costs for children with Down syndrome. American Journal of Medical Genetics Part A. 173(3). 627–637. 22 indexed citations
15.
McHorney, Colleen A., Concetta Crivera, François Laliberté, et al.. (2015). Abstract 13611: Adherence to Non-VKA Oral Anticoagulant Medications Based on the Pharmacy Quality Alliance Measure. Circulation. 132(suppl_3). 1 indexed citations
16.
Laliberté, François, Katherine Dea, Joyce LaMori, et al.. (2011). Abstract 9213: Risk of Gastrointestinal Conditions Among Patients with Atrial Fibrillation. Circulation. 124(suppl_21).
17.
Labiner, David M., Pierre Emmanuel Paradis, R Manjunath, et al.. (2010). Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology. 74(20). 1566–1574. 53 indexed citations
18.
Scheen, André, Nicolas Paquot, M. Castillo, & Patrick Lefèbvre. (1996). Traitement du diabète de type II insulino-requérant: intérêt potentiel de l'association insuline-antidiabétiques oraux. Open Repository and Bibliography (University of Liège).
19.
Scheen, André, Manuel J. Castillo, Nicolas Paquot, & Patrick Lefèbvre. (1996). No effect of neutralization of TNF-a on insulin-mediated glucose disposal in obese insulin-resistant subjects.. Open Repository and Bibliography (University of Liège). 1 indexed citations
20.
Scheen, André, et al.. (1988). Les cures de jeûne modifié, protidique ou glucido-protidique, dans le traitement de l'obésité morbide.. Open Repository and Bibliography (University of Liège). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Erzsébet Horváth–Puhó Breakdown of academic impact, for papers by Ad A. Kaptein Breakdown of academic impact, for papers by Michel Cucherat Breakdown of academic impact, for papers by Birgitta Stegmayr Breakdown of academic impact, for papers by Fabio Pellegrini Breakdown of academic impact, for papers by Nicholas L. Smith Breakdown of academic impact, for papers by Christian Mallen Breakdown of academic impact, for papers by Cheryl Bushnell Breakdown of academic impact, for papers by Cynthia L. Leibson Breakdown of academic impact, for papers by Petra Otterblad Olausson
Rankless by CCL
2026